The FDA typically follows the recommendations of its advisory panels but is not required to do so. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind ...
Eli Lilly’s (LLY) weight-loss medications may have benefits for people suffering from Alzheimer’s disease, according to new studies. Take advantage of TipRanks Premium at 55% off! Unlock powerful ...
Eli Lilly said it received marketing authorization from the European Commission for Kisunla, a treatment for early symptomatic Alzheimer's disease. Kisunla showed in a phase 3 trial that it can ...
Pharmaceutical Technology on MSN
Healthcare burden of neurological conditions “growing”, WHO warns
The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen strong treatment advancements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback